The microphthalmia family of transcription factors (MiT/TFEs) controls lysosomal biogenesis and is negatively regulated by the nutrient sensor mTORC1. However, the mechanisms by which cells with constitutive mTORC1 signaling maintain lysosomal catabolism remain to be elucidated. Using the murine epidermis as a model system, we found that epidermal Tsc1 deletion resulted in a phenotype characterized by wavy hair and curly whiskers, and was associated with increased EGFR and HER2 degradation. Unexpectedly, constitutive mTORC1 activation with Tsc1 loss increased lysosomal content via upregulated expression and activity of MiT/TFEs, whereas genetic deletion of Rheb or Rptor or prolonged pharmacologic mTORC1 inactivation had the reverse effect. This paradoxical increase in lysosomal biogenesis by mTORC1 was mediated by feedback inhibition of AKT, and a resulting suppression of AKT-induced MiT/TFE downregulation. Thus, inhibiting hyperactive AKT signaling in the context of mTORC1 loss-of-function fully restored MiT/TFE expression and activity. These data suggest that signaling feedback loops work to restrain or maintain cellular lysosomal content during chronically inhibited or constitutively active mTORC1 signaling, respectively, and reveal a mechanism by which mTORC1 regulates upstream receptor tyrosine kinase signaling.
Introduction
The microphthalmia family of transcription factors (MiT/TFEs) is composed of 4 conserved members (Mitf/Tfe3/Tfeb/Tfec) that are essential regulators of lysosomal biogenesis and autophagy. MiTs are functionally redundant and regulate transcription at CLEAR (coordinated lysosomal expression and regulation) motifs on lysosomal/ autophagy target genes. The regulation of MiT/TFE transcriptional activity is complex and understood to be governed by short-term subcellular localization changes driven principally by mTORC1 kinase signaling (1) . According to current models, phosphorylation of MiT/TFE proteins by mTORC1 leads to their cytoplasmic retention, resulting in decreased lysosomal biogenesis (2) (3) (4) (5) (6) . This is consistent with the known role of mTORC1, a key sensor of cellular nutrient levels, in the negative regulation of autophagy (7) . However, this model of MiT/TFE regulation raises an important question: how can cells maintain lysosomal content in the face of persistent mTORC1 signaling? Upregulated mTORC1 activity and lysosomal biogenesis must coexist during physiological states such as recovery from starvation (8) and physical exercise (9, 10) . Strikingly, several lines of evidence suggest that constitutive/prolonged mTORC1 activity may itself paradoxically activate lysosomal biogenesis via increased MiT/TFE activity.
In a small number of studies, constitutive mTORC1 hyperactivity (via Tsc1/2 loss) positively regulated transcription factor EB (TFE-B)-dependent lysosomal genes (11) and promoted TFE3 nuclear localization in an mTORC1-dependent manner (12, 13) , through undefined mechanisms. Furthermore, MiT/TFEs themselves stimulate mTORC1 activity in multiple cell types in response to nutrients, though their effect on cells with constitutive mTORC1 activation is less certain (14) . These findings suggest the intriguing possibility of an mTORC1-MiT/TFE-positive feedback loop. Notably, MiT/TFE activity is also coregulated by numerous oncogenic pathways in parallel to mTORC1, including ERK, GSK3, PKC, and AKT (15) (16) (17) . Taken together, these data raise the likelihood that mTORC1 regulation of MiT/TFE activity is more complex than previously appreciated.
As a first step to understanding how mTORC1 regulates MiT/TFE activity, we studied isogenic normal cells with or without genetic perturbations leading to constitutive or abrogated mTORC1 signaling. The epidermis and primary keratinocyte cultures provide a unique and well-characterized epithelial model system where the lysosome plays an important role in cellular differentiation and homeostasis (18) , thus we developed genetically engineered mouse models of Tsc1, Rheb, or Rptor conditional deletion in the epidermis. Herein, we demonstrate that in the context of long-term, bidirectional mTORC1 signaling perturbation, mTORC1 feedback to AKT prevails to regulate MiT/TFE levels and lysosomal biogenesis. These findings begin to explain how constitutive mTORC1 activation may upregulate lysosomal catabolism and provide a mechanism by which mTORC1 signaling feedback modulates upstream EGFR and HER2 activity.
The microphthalmia family of transcription factors (MiT/TFEs) controls lysosomal biogenesis and is negatively regulated by the nutrient sensor mTORC1. However, the mechanisms by which cells with constitutive mTORC1 signaling maintain lysosomal catabolism remain to be elucidated. Using the murine epidermis as a model system, we found that epidermal Tsc1 deletion resulted in a phenotype characterized by wavy hair and curly whiskers, and was associated with increased EGFR and HER2 degradation. Unexpectedly, constitutive mTORC1 activation with Tsc1 loss increased lysosomal content via upregulated expression and activity of MiT/TFEs, whereas genetic deletion of Rheb or Rptor or prolonged pharmacologic mTORC1 inactivation had the reverse effect. This paradoxical increase in lysosomal biogenesis by mTORC1 was mediated by feedback inhibition of AKT, and a resulting suppression of AKT-induced MiT/TFE downregulation. Thus, inhibiting hyperactive AKT signaling in the context of mTORC1 loss-of-function fully restored MiT/TFE expression and activity. These data suggest that signaling feedback loops work to restrain or maintain cellular lysosomal content during chronically inhibited or constitutively active mTORC1 signaling, respectively, and reveal a mechanism by which mTORC1 regulates upstream receptor tyrosine kinase signaling.
presence of Tsc1 fl/fl alleles and Krt14-Cre was confirmed by PCR genotyping ( Figure 1A ). TSC1 loss was verified by immunoblots from epidermal lysates ( Figure 1B ). In addition, we also prepared parallel primary keratinocyte cultures from these mice to further allow in vitro perturbation experiments in this system and confirm all in vivo findings ( Figure 1B ). Tsc1-cKO mice were viable and born in the expected Mendelian ratios. However, they could be distinguished by curly vibrissae at birth and coarse, wavy fur by 4 weeks ( Figure 1C ). During this period, Tsc1-cKO mice devel-
Results
Epidermal mTORC1 gain-of-function models have skin defects reminiscent of epidermal EGFR or TGF-α loss. Germline inactivation of Tsc1 is associated with embryonic lethality (19) . To study mTORC1 function in the epidermis, we examined mice with conditional deletion of epidermal Tsc1 by crossing floxed Tsc1 mice (Tsc1 fl/fl ) with Krt14-Cre mice (which express Cre recombinase driven by the keratin 14 promoter in the basal epidermis by E14.5), to generate Tsc1 fl/fl /Krt14-Cre mice (Tsc1-cKO). The showing presence of Rheb1 S16H fl/fl alleles, Rheb1 S16H excision alleles, and Krt14-Cre in Rheb1 S16H Tg mice. Rheb1 S16H transgenic mice show increased mTORC1 activity as seen by (G) p-S6 immunofluorescence. Scale bar: 150 μm. (H) Rheb1 S16H transgenic mice show presence of wavy fur, similar to Tsc1-cKO mice. jci.org Volume 129 Number 12 December 2019 (23) . Genotyping PCR confirmed the presence of S16H fl/fl alleles, S16H excision alleles, and Krt14-Cre in Rheb S16H transgenic (Tg) mice ( Figure 1F ). mTORC1 hyperactivity was confirmed by increased p-S6 levels by epidermal immunofluorescence and keratinocyte immunoblotting ( Figure 1G and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI128287DS1). These mice also had wavy fur ( Figure 1H ), confirming that the Tsc1-cKO phenotype was due to increased Rheb/mTORC1 activity.
oped epidermal thickening and showed increased p-S6 levels by immunofluorescence, consistent with increased mTORC1 activity ( Figure 1D ). By 6 months, Tsc1-cKO mice had hair loss and severe facial inflammation ( Figure 1E ), a phenotype strikingly similar to murine epidermal TGF-α or EGFR loss (20) (21) (22) . To verify mTORC1 dependency of this phenotype, we crossed K14cre mice with Rheb S16H fl/fl mice, which express a constitutively active Rheb transgene resistant to TSC GTPase-activating protein (GAP) activity expressed upon Cre excision of a loxp-stop-loxp elevated EGF-stimulated EGFR autophosphorylation in Rheb-cKO ( Figure 3F ), Rptor-cre ( Figure 3G ), and AZD8055-treated ( Figure  3H and Supplemental Figure 9E ) keratinocytes compared with controls, and with elevated and prolonged downstream ERK1/2 and AKT signaling in Rheb-cKO and Rptor-cre keratinocytes ( Figure 3F , Supplemental Figure 9A , and ref. 31 ). Finally, similar to Tsc1-cKO keratinocytes, levels of EGFR and HER2 transcripts were minimally altered in Rptor-cre keratinocytes (Supplemental Figure 2E ), indicating a posttranscriptional mechanism of gene regulation. Thus, mTORC1 activity is both necessary and sufficient to regulate EGFR and HER2 total protein expression and activity in the epidermis. mTORC1 stimulates EGF-induced EGFR degradation by promoting lysosomal biogenesis and activity. EGFR and HER2 levels are downregulated by ligand-induced internalization and lysosomal-mediated degradation (32) (33) (34) . We analyzed EGFR and HER2 degradation in response to exogenous EGF. Using highdose EGF to increase the rate of EGF-stimulated EGFR decay in control cells, the EGFR degradation rate was significantly slowed in Rptor-cre keratinocytes ( Figure 4 , A and B, and Supplemental Figure 3A using low-dose EGF), Rheb-cKO keratinocytes (Supplemental Figure 3 , B and C), and AZD8055-treated keratinocytes (Supplemental Figure 3 , D and E). Conversely, using low-dose EGF promoted only very minimal EGFR degradation in control keratinocytes, and the rate was significantly enhanced in Tsc1-cKO keratinocytes ( Figure 4 , C and D). These results raised the possibility that altered lysosomal degradation was mediating the EGFR levels with mTORC1 perturbation. Lysosomes are critical for the degradation of endocytosed or autophagocytosed cellular macromolecules. Lysosomal biogenesis is coordinated by the MiT/TFE subclass of basic helix-loop-helix transcription factors (TFEB/TFE3/MITF/TFEC), which drive transcription from consensus coordinated lysosomal expression and regulation (CLEAR) promoter elements on lysosomal/autophagy genes (5, 15, 35, 36) . To investigate lysosomal gene-expression changes downstream of mTORC1 loss-of-function, we performed microarray-based differential expression analysis of E18.5 epidermis from WT/Rptor-cKO mice. Out of 24,697 NCBI gene-annotated coding transcripts, we found 235 genes significantly (greater than 2 SD log 2 fold change) upregulated and 941 downregulated in Rptor-cKO compared with Rptor WT epidermis (Supplemental Table 1 ). We performed GSEA and found that a lysosomal gene signature panel (consisting of 360 lysosomal gene transcripts from the Mouse Lysosome Gene Database [mLGDB; http://lysosome.unipg.it/mouse.php]) was significantly negatively enriched in Rptor-cKO epidermis ( Figure  4E ). We validated GSEA results by immunoblotting for multiple MiT/TFE-regulated lysosomal proteins, which were downregulated in Rptor-cre and Rheb-cKO keratinocytes compared with their respective controls ( Figure 4F and Supplemental Figure 4 , A and B). Conversely, lysosomal/autophagy CLEAR target genes (36) were upregulated in Tsc1-cKO keratinocytes by quantitative real-time reverse transcriptase PCR (qRT-PCR) ( Figure 5A ) and in Tsc1-cKO epidermis ( Figure 5B ) and keratinocyte ( Figure  5C and Supplemental Figure 4C ) immunoblots in an mTORC1dependent manner ( Figure 5D ). CTSB/LAMP1 immunostaining revealed expansion of both lysosomal organelles in Tsc1-cKO epidermis ( Figure 5E ). Treatment of Tsc1-cre keratinocytes with the mTORC1 hyperactivation in Tsc1-cKO epidermis and keratinocytes downregulates EGFR and HER2 protein expression and activity. To assess whether the epidermal phenotype in Tsc1-cKO mice was due to a dysfunction in the EGF pathway, we examined expression of EGFR and its principal binding partner HER2. EGFR and HER2 protein expression were significantly decreased in P7 Tsc1-cKO epidermal lysates ( Figure 2A ) and keratinocytes ( Figure 2B ) and in Tsc1 fl/fl keratinocytes infected with adenovirus expressing cre recombinase (Tsc1-cre), compared with their respective controls, by immunoblotting ( Figure 2C ). Within the TSC1-TSC2 complex, TSC1 stabilizes TSC2 while TSC2 acts as a GAP for Rheb, and together the complex modulates mTORC1 activity. TSC2 expression in Tsc1-cKO epidermal lysates was decreased (Supplemental Figure 1B ) as previously described (24) . In addition, there was decreased EGFR and HER2 protein expression in Tsc2 fl/fl keratinocytes infected with adenoviral cre (Supplemental Figure 1C ). Membrane localized EGFR and HER2 in Tsc1-cKO keratinocytes was also decreased by surface biotinylation assays ( Figure 2D ). mTORC1 hyperactivity in Tsc1-cKO keratinocytes was confirmed by increased p-S6 levels by immunoblotting, and mTORC1 inhibition using rapamycin or mTOR kinase inhibitors AZD8055 or Torin1 increased EGFR and HER2 protein expression in Tsc1-cKO and Tsc1-cre keratinocytes ( Genetic and pharmacological inhibition of mTORC1 upregulates EGFR and HER2 protein expression and activity. Studies in cancer cell lines and MEFs have demonstrated that mTORC1 inhibition results in increased PI3K/AKT/MAPK signaling via feedback activation of RTK signaling. This is mediated by mTORC1-dependent phosphorylation of RTK adaptor proteins (IRS-1, GRB10) (25) (26) (27) or altered expression of RTKs (IGFR/IR/PDGFR) (28, 29) . However, the mechanism of the latter effect on RTK expression is poorly understood. At least one prior study has shown that pharmacologic mTORC1 inhibition also leads to feedback activation of EGFR (30) . We examined expression of EGFR and HER2 in mice with conditional epidermal loss of mTORC1 components Rheb or Rptor, as previously described (31) . mTORC1 loss-of-function was confirmed by decreased p-p70 S6 kinase and p-4E-BP1 levels in Rptor-cre keratinocyte lysates by immunoblotting (Supplemental Figure 2D ). Both Rheb fl/fl /Krt14-Cre (Rheb-cKO) keratinocytes as well as Rptor fl/fl keratinocytes infected with adenoviral cre recombinase (Rptor-cre) upregulated EGFR and HER2 protein expression compared with controls ( Figure 3A ). Membrane-localized EGFR and HER2 were concomitantly increased by immunofluorescence ( Figure 3B ) and surface biotinylation assays ( Figure 3C ). mTORC1 inhibitors (rapamycin, AZD8055, or Torin1) also elevated total ( Figure 3D ) and membrane ( Figure 3E ) EGFR and HER2 in WT keratinocytes. mTORC1 inactivation was associated with jci.org Volume 129 Number 12 December 2019 lysosomal V-ATPase inhibitor Bafilomycin A1 was sufficient to rescue EGFR expression, thus suggesting that increased lysosomal expression and/or activity was linked to EGFR loss in cells with constitutive mTORC1 signaling ( Figure 5F ). We further characterized lysosomal protein localization by examining expression of lysosomal proteins in lysosomalenriched fractions of keratinocyte lysates by immunoblotting, and found them to be increased in Tsc1-cre keratinocytes and Rheb1 S16H Tg keratinocytes relative to controls, and decreased in Rptorcre keratinocytes relative to controls ( Figure 6A ). Furthermore, the intensity of lysosomal LAMP2 ( Figure 6B ) and LAMP1 ( Figure  6C ) immunostaining was decreased in Rptor-cre keratinocytes relative to controls. Quantification of fluorescent intensity demonstrated a significant decrease in mean LAMP1 fluorescence in Rptor-cre keratinocytes ( Figure 6D ). Finally, to assess the activity of lysosomal enzymes, we incubated cells with Magic Red CTSB, a cathepsin B substrate that produces a cresyl violet fluorophore upon proteolytic cleavage, and measured fluorescence intensity by fluorometry. CTSB activity was significantly decreased in Rptor-cre keratinocytes, relative to controls ( Figure 6E ). mTORC1 drives total MiT/TFE expression, nuclear localization, and CLEAR promoter activity. To understand the basis for altered lysosomal gene expression/activity, we first queried total levels of MiT/TFE proteins, which were increased in Tsc1-cKO epidermis ( Figure 7A ) and keratinocytes in an mTORC1-sensitive manner ( Figure 7B ), and correspondingly decreased in Rptor-cKO epidermis ( Figure 7C ), Rptor-cre keratinocytes (Supplemental Figure 5A) , and Rheb-cKO keratinocytes (Supplemental Figure 5B ). Furthermore, MiT/TFE proteins were highly enriched in nuclear fraction immunoblots of Tsc1-cKO (Supplemental Figure 5C ) and Tsc1-cre (Figure 7 , D and E) keratinocytes in an mTORC1-dependent manner. TFE3 was also enriched in the basal nuclei of P7 Tsc1-cKO epidermis by immunohistochemistry (Supplemental Figure 5D ), and in the nuclei of Tsc1-cre keratinocytes by immunofluorescence ( Figure  7 , F and G) in an mTORC1-dependent manner (Supplemental Figure 5E ). MiT/TFE proteins were correspondingly decreased in Rptor-cre nuclei by nuclear lysate immunoblots (Supplemental Figure 5 , F-H) and immunofluorescence (Supplemental Figure 5I) . Importantly, short-term Torin1 treatment (1 hour) promoted, whereas long-term treatment (>24 hours) decreased, nuclear TFE3 by immunofluorescence (Supplemental Figure  6A ). We then determined corresponding changes in CLEAR promoter element activity by transfecting cells with a 4X-CLEAR luciferase reporter construct (containing 4 tandem copies of a CLEAR promoter element) (37) and measuring luciferase Figure 7J) , thus linking increased MiT/TFE transcriptional activity to EGFR and HER2 loss in cells with constitutive mTORC1 signaling.
Inhibition of hyperactive AKT in mTORC1-inhibited cells rescues autophagy/lysosomal biogenesis and downregulates EGFR expression.
Taken together, these data indicate that prolonged increases in mTORC1 activity upregulate lysosomal gene/protein expression via increased total and nuclear levels of MiTs and concomitant activity. 4X-CLEAR transactivation was significantly higher in Tsc1-cKO and Tsc1-cre keratinocytes (Figure 7 , H and I) and lower in Rptor-cre keratinocytes (Supplemental Figure 6B ) compared with their respective controls, linking MiT/TFE levels, CLEAR promoter activity, and altered lysosomal gene expression to mTORC1 status. Finally, in Tsc1-cre keratinocytes, combined MiT/TFE (TFEB/TFE3/MITF) siRNA treatment or single si RNA against these genes repressed expression of many lysosomal CLEAR target genes and proteins, with TFE3 and TFEB appearing to drive most of the effects in triple knockdown treat- motes MiT/TFE transcriptional activity (2-4). One mechanism for this apparent disconnect could be attributed to the activation of alternate signaling pathways bypassing mTORC1 or feedback loops downstream of mTORC1. For example Tsc2-deficient pri-CLEAR promoter activity. Similarly, genetic or longer-term pharmacologic mTORC1 inhibition decreased MiT levels and activity and lysosomal gene transcription. Yet these data are at odds with current models suggesting that mTORC1 suppression pro- S467/S565/S510 in TFEB, TFE3, and MITF, respectively, results in their cytoplasmic retention/inactivation (17, 39) or proteasomal degradation (1, 40) . We conducted a TMT-based phosphoproteomic analysis of control and Rptor-KO keratinocytes, and found p-TFE3 (S564/565) levels to be significantly increased in Rptor-mary neurons showed increased autolysosome formation and autophagic flux via AMPK-dependent ULK1 activation, bypassing mTORC1-dependent ULK1 inhibition (38) . Additionally, MiT/ TFE activity can be coregulated by numerous kinases, including AKT (15) (16) (17) . AKT phosphorylation at conserved RXXS/T motifs Lysosomes are critical for the degradation of cellular macromolecules and are transcriptionally regulated by MiT/TFE family members. Interestingly, upregulation of lysosomal function as well as mTORC1 activation are independently essential for epidermal differentiation and barrier function (18, 31) . However, the interdependence of mTOR signaling and lysosomal function has not been studied in the skin. Unexpectedly, differential expression analyses comparing epidermis from WT and Rptor-cKO mice revealed that lysosomal genes were significantly downregulated with mTORC1 loss-of-function in the epidermis. Accordingly, multiple lysosomal and autophagy CLEAR genes were upregulated with Tsc1 loss and downregulated with mTORC1 loss-of-function. Probing further upstream, mTORC1 signaling was required to increase the expression, nuclear localization, and transcriptional activity of MiTs, with a global increase in lysosomal content resulting in EGFR and HER2 downregulation.
Our finding that mTORC1 signaling was required to activate lysosomal biogenesis was initially unexpected given the previously established role of mTORC1 as a short-term negative regulator of MiT/TFE-driven lysosomal biogenesis (2) (3) (4) (5) (6) . We cannot exclude that our results may differ from previously published work in part because our studies used nonimmortalized primary cells exclusively, whereas other studies were predominantly performed in murine embryonic fibroblasts. However, a number of different lines of evidence have since emerged to suggest that the role of mTORC1 in lysosomal gene regulation is likely much more complex than previously thought. First, though initial studies performed in a limited number of cell lines showed that MiT/TFE activity was increased following shortterm mTORC1/2 inactivation with Torin1, short-term rapamycin did not affect TFEB phosphorylation or subcellular localization (3) . While this could represent rapamycin-insensitive functions of mTORC1, the long-term effects of pharmacological mTORC1 inactivation have not been described thus far. We now show that Torin1 treatment in excess of 24 hours significantly decreases MiT/TFE transcriptional activity. In support of our findings, one previous study reported that temporal mTORC1 inactivation by Torin1 activated TFEB for a limited duration of 1.5 hours, following which it was progressively inactivated (44) . Second, previous studies did not directly assess the impact of genetic or constitutive mTORC1 inactivation on lysosomal gene expression. We now show in an unbiased screen via GSEA, that mTORC1 lossof-function in Rptor-cKO epidermis downregulates multiple lysosomal genes bearing CLEAR regulatory motifs. Finally, in the context of Tsc1/2 loss, several studies have suggested that constitutive activation of mTORC1 paradoxically positively regulates MiT/TFE localization and activity, though the mechanism was not elucidated. Pena-Llopis et al. (11) showed that mTORC1 drives TFEB-dependent V-ATPase gene expression, further reinforcing their findings by publicly available gene expression data sets. Similarly, Tsc1/2 loss promoted TFE3 nuclear localization in ESC cells, Eker rat kidneys, and teratomas in an mTORC1dependent manner (12, 13) .
How can we begin to reconcile these apparently conflicting data? Significantly, MiT/TFE localization is regulated by multiple mTORC1-independent signaling pathways, including ERK and AKT. ERK2-mediated phosphorylation of TFEB at S142 KO keratinocytes compared with control (Supplemental Figure 8) , raising the possibility that AKT was modulating TFE3 activity in the context of Rptor loss. Like mTORC1, AKT can negatively regulate autophagy and lysosomal biogenesis (17, 41) . Thus, we tested whether AKT feedback activation in the context of long-term mTORC1 inhibition could inhibit MiT/TFE expression, nuclear localization, and/or activity.
AKT activation was increased in Rheb-cKO and Rptor-cre keratinocytes ( Figure 3F, Supplemental Figure 9A, and ref. 31) and decreased in Tsc1-cKO keratinocytes (Figure 2, E and F) , consistent with the presence of an mTORC1-AKT feedback loop, as previously documented in other systems (26-28, 42, 43) . Accordingly, incubation of Rptor-cre keratinocytes with AKT kinase inhibitors MK2206 ( Figure 8A ) or GDC-0068 (Supplemental Figure 9B ) rescued expression of lysosomal/autophagy target genes, autophagic flux, and MiT/ TFE proteins in a dose-dependent manner. MK2206 treatment also the increased the number and perinuclear localization of lysosomes as seen by LAMP1 immunostaining and LysoTracker Red fluorescence ( Figure 8 , B and C) and increased autophagic vesicles as seen by TEM ( Figure 8D ). This expansion of the lysosomal/autophagic compartment was driven by MiT/TFE activity since both MK2206 and GDC-0068 stimulated nuclear translocation of MiT/TFE proteins by immunoblot analyses (Figure 8E and Supplemental Figure  9C ) and MK2206 also promoted 4X-CLEAR promoter transactivation in luciferase assays ( Figure 8F ). Correspondingly, MK2206, GDC-0068, and another AKT kinase inhibitor AZD5363 downregulated EGFR and HER2 protein expression in Rptor-cre ( Figure 8G and Supplemental Figure 9D Figure 8H) . Conversely, adenoviral-mediated overexpression of constitutively activated myristolated (Myr) AKT1 or AKT2 in Tsc1-cKO keratinocytes downregulated lysosomal proteins and rescued EGFR and HER2 ( Figure 8I ). These findings confirmed that manipulation of AKT signaling, in the setting of mTORC1 loss or hyperactivity, was sufficient to alter MiT/TFE activity, lysosomal gene expression, and cellular EGFR and HER2 levels.
Discussion
To study the effects of constitutive mTORC1 signaling activation or suppression in epithelial tissues, we developed genetically engineered mouse models that allow specific perturbation of mTORC1 signaling in epidermal keratinocytes. We found that mice with epidermal mTORC1 activation developed a phenotype strikingly similar to murine epidermal TGF-α or EGFR loss (20) (21) (22) . Accordingly, Tsc1 loss in the epidermis suppressed EGFR and HER2 expression and activity, whereas mTORC1 loss-of-function via pharmacological inactivation, or Rheb/Rptor deletion in keratinocytes had the reverse effect. Among all surface receptors, EGFR signaling is prototypically regulated by ligand-induced lysosomal degradation. Significantly, the rate of EGFR decay was significantly enhanced in Tsc1-cKO keratinocytes and decreased in mTORC1-inhibited keratinocytes, confirming that mTORC1 signaling was both necessary and sufficient to regulate the net rate of ligand-induced EGFR degradation. jci.org Volume 129 Number 12 December 2019
teasome system (UPS). These are interactive and compensatory, wherein impairment of one upregulates the activity of the other (47) . The UPS carries out degradation of both short-lived regulatory and misfolded proteins, and long-lived ones that form the bulk of the cell (48) . However, the role of mTORC1 in the regulation of UPS proteolysis is complex and contextual, since both mTORC1 inhibition (49, 50) and activation (51) can upregulate proteasomal activity. One consequence of lysosomal/autophagy flux defects, seen in many lysosomal storage diseases, is the accumulation of poly-ubiquitinated proteins (52) . Interestingly, AKT activation can increase the ubiquitination and proteasomal degradation of specific substrates (53, 54) via phosphorylation, and MiT/TFE proteins are known bonafide proteasomal substrates (55, 56) that can be targeted for degradation by phosphorylation via multiple kinases including AKT (40) . Additionally, certain ubiquitin ligases involved in MiT/TFE regulation, such as STUB1 (56), are also responsible for the degradation of substrates in a PI3K/AKTdependent manner (54) . Further studies are required to determine the role of the UPS in MiT/TFE gene regulation, specific ubiquitin ligases or deubiquitinating enzymes (DUBs) modulating MiT/TFE turnover, the phospho-specific residues involved in this process, and the role of PI3K/AKT signaling in mediating this effect. In addition to enhancing our understanding of the role of mTORC1 signaling in the regulation of lysosomal biogenesis, our data have implications for keratinocyte differentiation and inflammatory skin disorders where mTOR signaling is frequently activated. There are several studies indicating that autophagy and lysosomal function are required for epidermal maturation (18, 57) . Thus, the downregulation of MiT/TFE expression and activity with mTORC1 loss-of-function may contribute to the keratinocyte differentiation and skin barrier defect we observed in previous work in the Rptor-cKO mice (31) . Accordingly, lysosomal dysfunction may also interfere with lipid biosynthesis, contributing to human skin disorders with defective barrier function such as atopic dermatitis (58) . In other inflammatory disorders such as psoriasis, mTORC1 signaling is hyperactivated (59) and lysosomal function or dysfunction may contribute to aberrant epidermal homeostasis (60) . In future studies, it will be of interest to investigate how changes in lysosomal biology downstream of mTORC1 signaling may be mechanistically important and potential therapeutic targets in inflammatory skin disease.
Methods

Mice
Animal protocols were approved by the Johns Hopkins University Animal Care and Use Committee. The following strains were used: mice expressing cre recombinase under control of the human K14 promoter (KRT14-cre) (stock number 004782, STOCK Tg(KRT14-cre)1Amc/J), mice carrying loxP sites flanking exons 17 and 18 of Tsc1 (stock number 005680, Tsc1 tm1Djk /J), mice carrying loxP sites flanking exons 2, 3, and 4 of Tsc2 (stock number 027458, Tsc2 tm1.1Mjgk /J), and mice carrying loxP sites flanking exon 6 of Rptor (stock number 013188, B6Cg-Rptor tm1.1Dmsa /J) were from The Jackson Laboratory; mice with loxP-flanked Rheb S16H alleles and mice with loxP-flanked Rheb1 alleles were generated in the laboratory of P.F. Worley (Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA). and AKT-mediated phosphorylation at S467/S565/S510 both promote cytosolic MiT/TFE retention and/or degradation (15, 17, 39, 40) . Though these previous studies focused on the role of AKT in phosphorylation and nuclear translocation of MiT/ TFE proteins, it is notable that we found both total and nuclear levels of MiT/TFEs to be proportionally affected by mTORC1 or AKT modulation. Thus, feedback activation of PI3K/AKT/ MAPK signaling following long-term mTORC1 inhibition (25) (26) (27) could potentially restrain MiTs, competing with the direct effects of mTORC1. This could also explain why shortterm Torin1 treatment promotes mTORC1-inhibited MiT/TFE nuclear localization (by also inhibiting AKT S473/T308 phosphorylation), whereas long-term treatment restrains mTORC1inhibited MiT/TFE nuclear localization (via feedback upregulation of AKT T308 phosphorylation) (43) . Consistent with this model, we observed the presence of an mTORC1-AKT negative feedback loop in epidermal keratinocytes. What factors could be driving feedback activation of AKT in the context of epidermal Rheb or Rptor loss? There are a number of known signaling intermediates (IRS-1, GRB10) and RTKs (HER3, IGFR, c-MET, PDGFR) which mediate this negative feedback signaling downstream of mTORC1 activity (25-29, 42, 43) . Here, we show that EGFR signaling is itself activated downstream of AKT signaling via a decrease in MiT/TFEmediated lysosomal biogenesis, further reinforcing this negative feedback to AKT. Accordingly, genetic and pharmacological inhibition of AKT in the context of Rheb or Rptor loss completely rescued MiT/TFE-driven transcriptional activity, lysosomal biogenesis, and downregulated EGFR and HER2, while overexpression of constitutively activated AKT in Tsc1-cKO keratinocytes downregulated lysosomal proteins and rescued EGFR and HER2. Notably, EGFR activation can independently trigger lysosomal dysfunction and mimic lysosomal storage diseases (45) , potentially synergizing with hyperactive AKT in the context of mTORC1 loss-of-function.
Another unexpected finding in our study is that mTORC1 signaling perturbation modulated lysosomal biogenesis by effects on MiT/TFE levels. While most previous studies have suggested that MiT/TFE activity is regulated via phosphorylation-mediated changes in nuclear-cytoplasmic distribution, several lines of evidence support that altering total levels of these proteins is sufficient to modulate their activity. Gene rearrangements or gene amplifications involving TFEB or MITF result in massive overexpression and constitutive nuclear localization of the full-length TFEB/MITF protein in tumor cells, and a similar mechanism occurs in TFE3-rearranged tumors (46) . Though we focused on the study of primary, nontransformed epithelial cells, we observed that in addition to nuclear levels, total MiT/TFE protein levels were dramatically upregulated with Tsc1 loss in an mTORC1-sensitive manner and downregulated with mTORC1 loss-of-function. AKT inhibition fully restored MiT/TFE transcriptional activity and concurrently elevated total levels of MiT/TFE proteins.
What are the potential mechanisms underlying mTORC1mediated MiT/TFE protein expression and/or turnover? It is known that cellular protein degradation is performed by 2 major systems, the autophagy-lysosome system and the ubiquitin-pro-
Primary mouse keratinocyte cultures
Primary mouse keratinocytes were isolated from newborn (P0/P7) skin. Newborn pups were decapitated, immersed in 7.5% povidoneiodine for 5 minutes, and rinsed in 70% ethanol for 2 minutes. The trunk skin was removed and placed dermis-side down in a Petri dish containing 0.25% trypsin-EDTA (Invitrogen) overnight at 4°C for 18 hours. The dermis was separated from the epidermis and keratinocytes isolated by scraping the basal surface of the epidermis. Keratinocyte cell suspensions were passed through a 100-μm cell strainer, centrifugated twice, and plated on Petri dishes coated with fibronectin (F1141; MilliporeSigma), in mouse keratinocyte medium (mKer) containing the following ingredients for a final volume of 500 mL: 3 parts low glucose DMEM (337.5 mL); 1 part Ham's F-12 (112.5 mL); 10% FBS (50 mL); penicillin (60 μg/mL) (1 mL of 10 4 U/mL stock); gentamycin (25 μg/mL) (250 μL of 50 mg/mL stock); insulin (5 μg/mL) (250 μL of 10 mg/mL stock); hydrocortisone (0.4 μg/mL) (200 μL of 1 mg/ mL stock); cholera toxin (10 -10 M) (5 μL of 1 mg/mL stock); transferrin (5 μg/mL) + 3,3-5′triiodo-L-thyronine (T3) (2 × 10 -9 M) (500 μL of a T3-transferrin stock).
To obtain keratinocytes with genetic ablation of Rptor or Tsc1, Rptor fl/fl or Tsc1 fl/fl keratinocytes were infected with Cre-recombinase-expressing or empty adenoviral vectors (Vector Biolabs), prior to plating cells. Lysosomal expression and activity assays Lysosomal fractionation assays. Lysosomal fractionation assays were carried out as previously described (62) . Cultured keratinocytes grown on 150 mm dishes were harvested and lysed in 750 mL of cold fractionation buffer (50 mM KCl, 90 mM potassium gluconate, 1 mM EGTA, 50 mM sucrose, 5 mM glucose, protease inhibitor cocktail tablet, and 20 mM HEPES, pH 7.4). The cells were then lysed by syringing, and nuclear fraction was removed by centrifugation at 1000g for 10 minutes at 4°C. The supernatant was then centrifuged at 20,000g for 30 minutes at 4°C. The precipitated lysosome-enriched fraction (LEF) was resuspended in the fractionation buffer, and the supernatant was separated as the cytosolic fraction. Cathepsin B activity assays. To measure lysosomal cathepsin B activity, cells were incubated with Magic Red Cathepsin B (Biorad) for 1 hour and processed according to the manufacturer's instructions for fluorescence plate reader analysis.
Reagents and antibodies
Immunocytochemistry
Primary mouse keratinocytes were seeded on coverslips coated with fibronectin. Following experimental treatments, cells were either fixed epitope retrieval) method, in accordance with the protocol specified for each antibody. All washing steps were done using 1X TBS-T buffer. Endogenous peroxidase activity was quenched by incubation with Dual Enzyme Block (Dako, Agilent Technologies) for 10 minutes at room temperature. Sections were incubated with each antibody overnight at 4°C diluted in antibody dilution buffer (Roche/Ventana Medical Systems). For immunohistochemistry, a horseradish peroxidase-labeled polymer, Poly-HRP PowerVision Detection System (Novocastra/Leica Biosystems), was applied for 30 minutes at room temperature. Signal detection was performed using DAB (Sigma-Aldrich) for 20 minutes at room temperature. Slides were counterstained for 30 seconds with Mayer's hematoxylin (Dako, Agilent Technologies), dehydrated, and mounted. For immunofluorescence, after primary antibody overnight reaction at 4°C, sections were incubated with secondary antibodies (Alexa Fluor 488-or Alexa Fluor 594-conjugated, anti-rabbit or anti-mouse IgG; Thermo Fisher Scientific) at a dilution of 1:200 for 1 hour 30 minutes at room temperature. Subsequently, they were washed 2 times for 5 minutes each time in PBS, rinsed in distilled water, dehydrated in graded ethanol, and mounted with ProLong Gold Antifade with DAPI (Thermo Fisher Scientific). IHC for TFE3 was carried out as previously described (61) .
Protein lysate preparation and immunoblotting
Mouse epidermis was separated from the dermis following incubation of pup skin with 3.8% ammonium thiocyanate (catalog A7149, Sigma-Aldrich) for 10 minutes at room temperature. The epidermal sheet was homogenized using gentleMACS M tubes in the gentleMACS dissociator (Miltenyi Biotec). Tissues or cells were homogenized and lysed in ice-cold 1X Mg 2+ lysis/wash buffer (catalog 20-168, MilliporeSigma) or RIPA buffer (catalog R0278, MilliporeSigma) supplemented with NaVO 4 (1 mM), NaF (1 mM), and 10 μL Halt Protease and Phosphatase Inhibitor Cocktail (catalog 78440, Thermo Fisher Scientific) in 1 mL buffer for 15 minutes on ice. Lysates were sheared by passing through 20-, 22-, 25-, and 26-gauge needles progressively, centrifuged at 21,300 g for 10 minutes at 4°C, and supernatants collected. Protein concentrations were quantified using the BCA Protein Assay Kit (catalog 23225, Pierce), and 5-10 μg protein was resolved on a 1.5mm, 3%-8% Tris-Acetate or 4%-12% Bis-Tris SDS-PAGE gel (Thermo Fisher Scientific). Protein was transferred to nitrocellulose membranes (Amersham Bioscience). Membranes were allowed to block for 1 hour at room temperature in 5% nonfat milk in 1X TBS-T and then incubated overnight with a primary antibody diluted in 5% BSA in 1X TBS-T. The secondary antibodies used were anti-rabbit or anti-mouse Ig as appropriate (Cell Signaling) and diluted at 1:1000 in 5% nonfat milk in 1X TBS-T. Blots were developed using a chemiluminescent development solution (Super Signal West Femto, Pierce) and bands were imaged on a chemiluminescent imaging system (ChemiDoc Touch imaging System, Biorad) or MicroChemi Chemiluminescent Imager (FroggaBio Inc.). Digital images were quantified using background correction on the Alpha Innotech system (Protein Simple) and all bands were normalized to their respective β-actin, tubulin, or GAP-DH expression levels as loading controls. Nuclear lysates were prepared using the PARIS kit (catalog AM1921, Thermo Fisher Scientific) according to manufacturer's instructions. Digital images were quantified using background correction on the Alpha Innotech system and all bands were normalized to their respective lamin, histone H3, or fibrillarin levels as loading controls. Cell surface biotinylation was jci.org Volume 129 Number 12 December 2019
were postfixed in 1% osmium tetroxide in 0.1M sodium cacodylate for 1 hour on ice in the dark, rinsed twice with distilled water for 5 minutes, stained with 2% aqueous uranyl acetate (0.22 μm filtered) for 1 hour in the dark, followed by dehydration in an ascending grade of ethanol (50%, 70%, 90%, and 100%; thrice each), and embedded in an epoxy resin. The resin was allowed to polymerize at 37°C overnight for 2-3 days followed by 60°C overnight. Grids were stained with 2% uranyl acetate in 50% methanol, followed by lead citrate, and observed with a Philips CM120 at 80 kV. Images were captured with an AMT XR80 high-resolution (16-bit) 8 megapixel camera.
Microarray analysis
Microarray-based differential expression analysis of E18.5 epidermis from WT/Rptor-cKO mice was carried out as described in Supplemental Methods. All original microarray data were deposited in the NCBI's Gene Expression Omnibus database (GEO 124754).
Statistics
For image analysis, RNA and protein quantification and luciferase assays, statistical significance was determined using the unpaired, 2-tailed Student's t test when comparing 2 experimental groups, or with 1-way ANOVA with Tukey's correction when comparing 3 or more experimental groups. All tests were performed in Prism 8 (GraphPad). P values of less than 0.05 were considered statistically significant.
Phosphoproteome analysis
TMT-based phosphoproteome analysis of control or Rptor-KO mouse primary keratinocytes was carried out as described in Supplemental Methods.
